Moderna raises 2026 outlook as CEO says newer vaccines are gaining traction
CNBC · Annika Kim Constantino ·
The biotech company now expects 2026 revenue growth of 15% to 25%, up from its previous guidance of up to 10%.
Moderna on Friday smashed third-quarter revenue and earnings estimates and hiked its outlook for full-year sales growth, as some of its newer products gain momentum and Covid vaccine revenue outperforms.
Shares of Moderna rose roughly 3% in premarket trading on Friday.
The biotech company now expects 2026 revenue growth of 15% to 25%, up from its previous guidance of up to 10%.